Leading the next-generation of bioconjugate drug technology
SelecAll™ Platform Technology
The Next-Generation of Innovative Biological Drugs to Satisfy the Unmet Global Demand
SelecAll™
Next-generation bio-conjugates
Designed to overcome the limitations of conventional conjugation approaches
Protein-Albumin Conjugate
Protein-Albumin Conjugate
Long-acting effect in serum
Fewer injections and lower dosage
Minimize loss of drug efficacy
High conjugation yield and fast reaction
Minimize toxicity of drug
(low immunogenicity)
Manufacture homogeneous drug
Therapeutic Drugs
Protein, Peptide,
Antibody
Human Recombinant Albumin
Increased half-life, Recycling through FcRn binding, Low immunogenicity
Linker
High yield, fast reaction,
Minimize loss of activity
SelecAll™
Potential to provide fundamental breakthroughs in drug design
Therapeutic Proteins
Proteins/Peptides
Antibodies
Chemical drugs
Core Technology1
Site-specific bioconjugation
Linker
PEG or non-PEG Linker
Multi-arm Linker
Cleavable Linker
Core Technology2
Linker Technology
Carrier
Human Serum Albumin
Fc domain
Albumin binding domain
PEG
Core Technology3
Recombinant Human Serum Albumin
Manufacture homogeneous product of protein conjugates
with retention of protein structure and protein activity
Conventional bioconjugation
Lysine Conjugation
Random conjugation results in protein structure deformation
Loss of protein efficacy
Heterogeneous mixture of protein conjugates
Difficulty purifying product
SelecAll™ Technology Platform
Site-specific Bioconjugation
Retention of protein structure
Retention of protein activity
Homogeneous product of protein conjugates
Simple product purification
(Cell lysis → Direct conjugation process → Purification → final DS)
High conjugation yield, stability and fast reaction through ‘click chemistry’
Yield
>90%
Drug-Albumin Conjugate
Applicable to various proteins, peptides, and antibody drugs
High Technology Scalability
Minimize
Loss of
Drug Efficacy
Maintain
Drug’s Intrinsic
Characteristics
Minimize
Adverse Effects
(Toxicity &
Immunogenicity)
Homogenous
Drug
Preparation
Cost-effective
Manufacturing
Process
Applicable to various drugs using site-specific
Albumination platform technology
Albumin plays a role in nutrient and drug delivery, can potentially be used for the development of long-acting drugs with long half-life
Distribution and Role
- Albumin is synthesized in the liver and accounts for about 60% of protein in blood (35 ~ 45 g/L)
- Controls osmotic pressure, transports nutrients, drugs, and foreign substances in the body
- Disease detection by measuring the amount of albumin in the blood
Characteristics
- High solubility and stability (pH, Temp.)
- Cysteine-34 for chemical conjugation of peptides and scavenging against free radicals
- Long half-life in vivo (3 weeks)
- Non-immunogenic
FcRn-mediated recycling
Albumin binds with FcRn and the bond remains unbroken,
maintaining a half-life
of over 3 weeks
